Novo Nordisk to increase manufacturing capacity of weight-loss drugs
FRANKFURT (Reuters) – Novo Nordisk said it will boost manufacturing capacity for future obesity drug launches and worry less about marketing and advertising after a bungled market introduction of its Wegovy injection last year.